Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Hyaluronic acid + triamcinolone acetonide** is a combination drug designed for *intra-articular injection* for the treatment of musculoskeletal disorders, especially osteoarthritis. **Hyaluronic acid** is a polysaccharide that acts as a lubricant and shock absorber within joint spaces, improving joint function and reducing pain. **Triamcinolone acetonide** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive activity. In combination, these agents aim to simultaneously replenish joint lubrication and suppress local inflammation to relieve pain and improve mobility[5][3]. Studies indicate that such combinations may offer improved and sustained symptomatic relief compared to hyaluronic acid alone, though prolonged use or high doses may increase risk of cartilage damage[3]. Primary indications include osteoarthritis (particularly of the knee), but combinations may be researched or used for other joint inflammatory disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + triamcinolone acetonide.